Renowned Cancer Experts to Probe Complexities of MDS at ASCP 2013 Chicago
Monday, July 22, 2013
Myelodysplastic Syndromes (MDS) is a rare blood disorder that is difficult to diagnose and transforms into acute myelogenous leukemia in about one third of patients with MDS. Patients who have MDS are frequently misdiagnosed or diagnosed when cancer is in its late stages.
“The first challenge is that physicians are not recognizing that the clinical characteristics consistent with MDS are abnormal. A second challenge, from a pathologist’s standpoint, is that MDS is a tough diagnosis to make.”
—Mikkael Sekeres, MD, MS
ASCP 2013 Chicago will offer a unique symposium, bringing together a multidisciplinary team of renowned oncologists, hematopathologists, flow cytometrists, and cytogeneticists and molecular geneticists to probe the complexities of diagnosing and treating MDS, and examining emerging technologies to treat the often deadly disease.
“The Diagnosis, Classification, and Clinical Care of Myelodysplastic Syndromes (DC3-MDS)” will be held on Sept. 20 from 3:15 to 6:05 p.m. and will simultaneously be broadcast worldwide via a live webinar for free. Registration for the webinar is limited. Participants may enroll for the webinar on a first-come, first-serve basis.
“The first challenge is that physicians are not recognizing that the clinical characteristics consistent with MDS are abnormal,” says Mikkael Sekeres, MD, MS, Professor of Medicine and Director of Leukemia Program at the Cleveland Clinic, Cleveland, one of the symposium presenters and world renowned expert on MDS. “A second challenge, from a pathologist’s standpoint, is that MDS is a tough diagnosis to make.”
The diagnosis cannot be made in isolation and requires effective communication among all members of the MDS medical team. If there is not a uniform method of expressing what the diagnosis is, it leads to misinterpretation.
This symposium is intentionally designed to present an interactive dialogue between the pathologists and clinicians who discuss the clinical approach, diagnosis, classification, and clinical care of patients with MDS.
In addition to Dr. Sekeres, presenters include:
Maria R. Baer, MD, Professor of Medicine and Molecular Medicine at the University of Maryland School of Medicine, Baltimore, where she is also the Director of Hematologic Malignancies at the Marlene and Stewart Greenebaum Cancer Center;
Magdalena B. Czader, MD, PhD, FASCP, Associate Professor at the Indiana University School of Medicine, Indianapolis, where she is also Director of Hematopathology and director of the Hematopathology Fellowship Program;
Charles Goolsby, PhD, Professor of Pathology at the
Feinberg School of Medicine at Northwestern University, Evanston, Ill.;
Michelle M. Le Beau, PhD, Professor of Medicine in the Section of Hematology/Oncology and Director of the University of Chicago Comprehensive Cancer Center, Chicago, and Director of the University’s Cancer Cytogenetics Laboratory; and
Kaari K. Reichard, MD FASCP, Pathologist in the Division of Hematopathology at the Mayo Clinic Medical Laboratories, Rochester, Minn.
The symposium and live webinar are funded by an educational grant from the Celgene Corporation, based in Summit, N.J. To register for the live webinar, click here. For more resources about MDS, click here.